Biogen welcomes the U.S. Veterans Health Administration’s (VHA) recent decision to provide coverage of LEQEMBITM for veterans living with early stages of Alzheimer’s disease. Additional details can be found in Eisai’s news release announcing the coverage decision.
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
